The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer

European Journal of Gynaecological Oncology

Volumn 24, Issue 1, 2003, Pages 60-62

  Valenzuela, P ^a,b   Mateos, S ^a   Tello, E ^a   Lopez Bueno M J ^a   Garrido, N ^a   Gaspar, M J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Breast cancer; CA 15.3; CEA; Follow up; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037289277     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rosen P. R., Groshen S., Saigo P. E., Kinne D. W., Hellman S.: "A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma". J. Clin. Oncol., 1989, 7, 355.
2. Hayes D. F.: "Serum (circulating) tumor markers for breast cancer". Recent Results Cancer Res., 1996, 140, 101.
3. Gold P., Freedman S. O.: "Specific carcinoembryonic antigens of the human digestive system". J. Exp. Med., 1965, 122, 467.
4. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J.: "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus bening breast tumors". Hybridoma, 1984, 3, 223.
5. Winchester D. P., Sener S. F., Khandekar J. D., Oviedo M. A., Cunningham M. P., Caprini J. A. et al.: "Symptomatology as an indicator of recurrent or metastatic breast cancer". Cancer, 1979, 43, 956.
6. Stierer M., Rosen H. R.: "Influence of early diagnosis on prognosis of recurrent breast cancer". Cancer, 1989, 64, 1128.
7. Broyn T., Froyen J.: "Evaluation of routine follw-up after surgery for breast carcinoma". Acta Chir. Scand., 1982, 148, 401.
8. American Society of Clinical Oncology: "Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer". J. Clin. Oncol., 1996, 14, 2843.
9. Bast Rc. Jr., Ravdin P., Hayes D. F., Bates S., Fritsche H. Jr., Jessup J. M. et al.: "2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology". J. Clin. Oncol., 2001, 19, 1865.
10. Lumachi F., Brandes A. A., Boccagni P., Polistina F., Favia G., D'amico D. F.: "Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3". Anticancer Res., 1999, 19, 4485.
11. Lauro S., Trasatti L., Bordin F., Lanzetta G., Bria E., Gelibter A. et al.: "Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients". Anticancer Res., 1999, 19, 3511.
12. Sütterlin M., Bussen S., Trott S., Caffier H.: "Predicitve value of CEA and CA 15-3 in the follow up of invasive breast cancer". Anticancer Res., 1999, 19, 2567.
13. Sauer H.: "Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer". Anticancer Res., 1997, 17, 3059.
14. Molina R., Jo J., Filella X., Zanón G., Farrus B., Muñoz M. et aL: "C-erbB-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients". Anticancer Res., 1999, 19, 2551.